{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T23:39:42Z","timestamp":1790033982486,"version":"4.0.1"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Epigenet"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1186\/1868-7083-5-13","type":"journal-article","created":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T08:14:49Z","timestamp":1375344889000},"source":"Crossref","is-referenced-by-count":50,"title":["The combination of valproic acid, all-trans retinoic acid and low-dose cytarabine as disease-stabilizing treatment in acute myeloid leukemia"],"prefix":"10.1186","volume":"5","author":[{"given":"Hanne","family":"Fredly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Ersv\u00e6r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid Olsnes","family":"Kittang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Galina","family":"Tsykunova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f8rn Tore","family":"Gjertsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d8ystein","family":"Bruserud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,8,1]]},"reference":[{"key":"59_CR1","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1002\/ajh.22246","volume":"87","author":"EH Estey","year":"2012","unstructured":"Estey EH: Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management. Am J Hematol. 2012, 87: 89-99. 10.1002\/ajh.22246. s","journal-title":"Am J Hematol"},{"key":"59_CR2","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1093\/annonc\/mdj112","volume":"17","author":"R Latagliata","year":"2006","unstructured":"Latagliata R, Bongarzoni V, Carmosino I, Mengarelli A, Breccia M, Borza PA, D'Andrea M, D'Elia GM, Mecarocci S, Morano SG: Acute myelogenous leukemia in elderly patients not eligible for intensive chemotherapy: the dark side of the moon. Ann Oncol. 2006, 17: 281-285.","journal-title":"Ann Oncol"},{"key":"59_CR3","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1111\/j.1365-2141.2010.08470.x","volume":"152","author":"DA Pollyea","year":"2011","unstructured":"Pollyea DA, Kohrt HE, Medeiros BC: Acute myeloid leukemia in the elderly: a review. Br J Haematol. 2011, 152: 524-542. 10.1111\/j.1365-2141.2010.08470.x.","journal-title":"Br J Haematol"},{"key":"59_CR4","doi-asserted-by":"publisher","first-page":"4422","DOI":"10.1182\/blood-2010-03-276485","volume":"116","author":"H Kantarjian","year":"2010","unstructured":"Kantarjian H, Ravandi F, O'Brien S, Cortes J, Faderl S, Garcia-Manero G, Jabbour E, Wierda W, Kadia T, Pierce S: Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. Blood. 2010, 116: 4422-4429. 10.1182\/blood-2010-03-276485.","journal-title":"Blood"},{"key":"59_CR5","doi-asserted-by":"publisher","first-page":"4417","DOI":"10.1200\/JCO.2011.35.7525","volume":"29","author":"RB Walter","year":"2011","unstructured":"Walter RB, Othus M, Borthakur G, Ravandi F, Cortes JE, Pierce SA, Appelbaum FR, Kantarjian HA, Estey EH: Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment. J Clin Oncol. 2011, 29: 4417-4423. 10.1200\/JCO.2011.35.7525.","journal-title":"J Clin Oncol"},{"key":"59_CR6","doi-asserted-by":"publisher","first-page":"388","DOI":"10.2174\/138920107783018417","volume":"8","author":"O Bruserud","year":"2007","unstructured":"Bruserud O, Stapnes C, Ersvaer E, Gjertsen BT, Ryningen A: Histone deacetylase inhibitors in cancer treatment: a review of the clinical toxicity and the modulation of gene expression in cancer cell. Curr Pharm Biotechnol. 2007, 8: 388-400. 10.2174\/138920107783018417.","journal-title":"Curr Pharm Biotechnol"},{"key":"59_CR7","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1517\/14728222.10.1.51","volume":"10","author":"O Bruserud","year":"2006","unstructured":"Bruserud O, Stapnes C, Tronstad KJ, Ryningen A, Anensen N, Gjertsen BT: Protein lysine acetylation in normal and leukemic hematopoiesis: HDACs as possible therapeutic targets in adult AML. Expert Opin Ther Targets. 2006, 10: 51-68. 10.1517\/14728222.10.1.51.","journal-title":"Expert Opin Ther Targets"},{"key":"59_CR8","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1159\/000160599","volume":"31","author":"F Bellos","year":"2008","unstructured":"Bellos F, Mahlknecht U: Valproic acid and all-trans retinoic acid: meta-analysis of a palliative treatment regimen in AML and MDS patients. Onkologie. 2008, 31: 629-633.","journal-title":"Onkologie"},{"key":"59_CR9","doi-asserted-by":"publisher","first-page":"2717","DOI":"10.1002\/cncr.21589","volume":"104","author":"G Bug","year":"2005","unstructured":"Bug G, Ritter M, Wassmann B, Schoch C, Heinzel T, Schwarz K, Romanski A, Kramer OH, Kampfmann M, Hoelzer D: Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia. Cancer. 2005, 104: 2717-2725. 10.1002\/cncr.21589.","journal-title":"Cancer"},{"key":"59_CR10","doi-asserted-by":"publisher","first-page":"8903","DOI":"10.1158\/0008-5472.CAN-05-2726","volume":"66","author":"G Cimino","year":"2006","unstructured":"Cimino G, Lo-Coco F, Fenu S, Travaglini L, Finolezzi E, Mancini M, Nanni M, Careddu A, Fazi F, Padula F: Sequential valproic acid\/all-trans retinoic acid treatment reprograms differentiation in refractory and high-risk acute myeloid leukemia. Cancer Res. 2006, 66: 8903-8911. 10.1158\/0008-5472.CAN-05-2726.","journal-title":"Cancer Res"},{"issue":"Suppl 1","key":"59_CR11","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s00277-005-0026-8","volume":"84","author":"A Kuendgen","year":"2005","unstructured":"Kuendgen A, Knipp S, Fox F, Strupp C, Hildebrandt B, Steidl C, Germing U, Haas R, Gattermann N: Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia. Ann Hematol. 2005, 84 (Suppl 1): 61-66.","journal-title":"Ann Hematol"},{"key":"59_CR12","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1002\/cncr.21552","volume":"106","author":"A Kuendgen","year":"2006","unstructured":"Kuendgen A, Schmid M, Schlenk R, Knipp S, Hildebrandt B, Steidl C, Germing U, Haas R, Dohner H, Gattermann N: The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia. Cancer. 2006, 106: 112-119. 10.1002\/cncr.21552.","journal-title":"Cancer"},{"key":"59_CR13","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1002\/cncr.21132","volume":"104","author":"C Pilatrino","year":"2005","unstructured":"Pilatrino C, Cilloni D, Messa E, Morotti A, Giugliano E, Pautasso M, Familiari U, Cappia S, Pelicci PG, Lo Coco F: Increase in platelet count in older, poor-risk patients with acute myeloid leukemia or myelodysplastic syndrome treated with valproic acid and all-trans retinoic acid. Cancer. 2005, 104: 101-109. 10.1002\/cncr.21132.","journal-title":"Cancer"},{"key":"59_CR14","first-page":"986","volume":"90","author":"E Raffoux","year":"2005","unstructured":"Raffoux E, Chaibi P, Dombret H, Degos L: Valproic acid and all-trans retinoic acid for the treatment of elderly patients with acute myeloid leukemia. Haematologica. 2005, 90: 986-988.","journal-title":"Haematologica"},{"key":"59_CR15","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.leukres.2008.10.005","volume":"33","author":"A Ryningen","year":"2009","unstructured":"Ryningen A, Stapnes C, Lassalle P, Corbascio M, Gjertsen BT, Bruserud O: A subset of patients with high-risk acute myelogenous leukemia shows improved peripheral blood cell counts when treated with the combination of valproic acid, theophylline and all-trans retinoic acid. Leuk Res. 2009, 33: 779-787. 10.1016\/j.leukres.2008.10.005.","journal-title":"Leuk Res"},{"key":"59_CR16","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/j.leukres.2011.02.021","volume":"35","author":"MT Corsetti","year":"2011","unstructured":"Corsetti MT, Salvi F, Perticone S, Baraldi A, De Paoli L, Gatto S, Pietrasanta D, Pini M, Primon V, Zallio F: Hematologic improvement and response in elderly AML\/RAEB patients treated with valproic acid and low-dose Ara-C. Leuk Res. 2011, 35: 991-997. 10.1016\/j.leukres.2011.02.021.","journal-title":"Leuk Res"},{"key":"59_CR17","doi-asserted-by":"publisher","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","volume":"21","author":"BD Cheson","year":"2003","unstructured":"Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH, Schiffer CA, Doehner H, Tallman MS, Lister TA: Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003, 21: 4642-4649. 10.1200\/JCO.2003.04.036.","journal-title":"J Clin Oncol"},{"key":"59_CR18","first-page":"3671","volume":"96","author":"BD Cheson","year":"2000","unstructured":"Cheson BD, Bennett JM, Kantarjian H, Pinto A, Schiffer CA, Nimer SD, Lowenberg B, Beran M, de Witte TM, Stone RM: Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood. 2000, 96: 3671-3674.","journal-title":"Blood"},{"key":"59_CR19","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","volume":"108","author":"BD Cheson","year":"2006","unstructured":"Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, Pinto A, Beran M, de Witte TM, Stone RM: Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006, 108: 419-425. 10.1182\/blood-2005-10-4149.","journal-title":"Blood"},{"key":"59_CR20","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1080\/09537100600746508","volume":"17","author":"A Ryningen","year":"2006","unstructured":"Ryningen A, Apelseth T, Hausken T, Bruserud O: Reticulated platelets are increased in chronic myeloproliferative disorders, pure erythrocytosis, reactive thrombocytosis and prior to hematopoietic reconstitution after intensive chemotherapy. Platelets. 2006, 17: 296-302. 10.1080\/09537100600746508.","journal-title":"Platelets"},{"key":"59_CR21","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/1471-2172-11-38","volume":"11","author":"E Ersvaer","year":"2010","unstructured":"Ersvaer E, Liseth K, Skavland J, Gjertsen BT, Bruserud O: Intensive chemotherapy for acute myeloid leukemia differentially affects circulating TC1, TH1, TH17 and TREG cells. BMC Immunol. 2010, 11: 38-10.1186\/1471-2172-11-38.","journal-title":"BMC Immunol"},{"key":"59_CR22","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","volume":"106","author":"ML Sorror","year":"2005","unstructured":"Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, Storer B: Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005, 106: 2912-2919. 10.1182\/blood-2005-05-2004.","journal-title":"Blood"},{"key":"59_CR23","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1111\/j.1365-2141.2006.06476.x","volume":"136","author":"FJ Giles","year":"2007","unstructured":"Giles FJ, Borthakur G, Ravandi F, Faderl S, Verstovsek S, Thomas D, Wierda W, Ferrajoli A, Kornblau S, Pierce S: The hematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukemia. Br J Haematol. 2007, 136: 624-627. 10.1111\/j.1365-2141.2006.06476.x.","journal-title":"Br J Haematol"},{"key":"59_CR24","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"MM Oken","year":"1982","unstructured":"Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982, 5: 649-655. 10.1097\/00000421-198212000-00014.","journal-title":"Am J Clin Oncol"},{"key":"59_CR25","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.critrevonc.2008.07.015","volume":"69","author":"SM Alibhai","year":"2009","unstructured":"Alibhai SM, Leach M, Gupta V, Tomlinson GA, Brandwein JM, Saiz FS, Minden MD: Quality of life beyond six months after diagnosis in older adults with acute myeloid leukemia. Crit Rev Oncol Hematol. 2009, 69: 168-174. 10.1016\/j.critrevonc.2008.07.015.","journal-title":"Crit Rev Oncol Hematol"},{"key":"59_CR26","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/S0305-7372(03)00142-7","volume":"30","author":"A Redaelli","year":"2004","unstructured":"Redaelli A, Stephens JM, Brandt S, Botteman MF, Pashos CL: Short- and long-term effects of acute myeloid leukemia on patient health-related quality of life. Cancer Treat Rev. 2004, 30: 103-117. 10.1016\/S0305-7372(03)00142-7.","journal-title":"Cancer Treat Rev"},{"key":"59_CR27","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.critrevonc.2007.07.003","volume":"64","author":"SM Alibhai","year":"2007","unstructured":"Alibhai SM, Leach M, Kermalli H, Gupta V, Kowgier ME, Tomlinson GA, Brandwein J, Buckstein R, Minden MD: The impact of acute myeloid leukemia and its treatment on quality of life and functional status in older adults. Crit Rev Oncol Hematol. 2007, 64: 19-30. 10.1016\/j.critrevonc.2007.07.003.","journal-title":"Crit Rev Oncol Hematol"},{"key":"59_CR28","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.smim.2007.10.004","volume":"19","author":"KM Williams","year":"2007","unstructured":"Williams KM, Hakim FT, Gress RE: T cell immune reconstitution following lymphodepletion. Semin Immunol. 2007, 19: 318-330. 10.1016\/j.smim.2007.10.004.","journal-title":"Semin Immunol"},{"key":"59_CR29","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1002\/ijc.25791","volume":"129","author":"Z Shenghui","year":"2011","unstructured":"Shenghui Z, Yixiang H, Jianbo W, Kang Y, Laixi B, Yan Z, Xi X: Elevated frequencies of CD4 CD25 CD127lo regulatory T cells is associated to poor prognosis in patients with acute myeloid leukemia. Int J Cancer. 2011, 129: 1373-1381. 10.1002\/ijc.25791.","journal-title":"Int J Cancer"},{"key":"59_CR30","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1111\/j.1365-2249.2009.04011.x","volume":"158","author":"C Wu","year":"2009","unstructured":"Wu C, Wang S, Wang F, Chen Q, Peng S, Zhang Y, Qian J, Jin J, Xu H: Increased frequencies of T helper type 17 cells in the peripheral blood of patients with acute myeloid leukemia. Clin Exp Immunol. 2009, 158: 199-204. 10.1111\/j.1365-2249.2009.04011.x.","journal-title":"Clin Exp Immunol"},{"key":"59_CR31","doi-asserted-by":"publisher","first-page":"3325","DOI":"10.1158\/1078-0432.CCR-08-3010","volume":"15","author":"MJ Szczepanski","year":"2009","unstructured":"Szczepanski MJ, Szajnik M, Czystowska M, Mandapathil M, Strauss L, Welsh A, Foon KA, Whiteside TL, Boyiadzis M: Increased frequency and suppression by regulatory T cells in patients with acute myelogenous leukemia. Clin Cancer Res. 2009, 15: 3325-3332. 10.1158\/1078-0432.CCR-08-3010.","journal-title":"Clin Cancer Res"},{"key":"59_CR32","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/j.1751-553X.2007.00993.x","volume":"30","author":"H Michur","year":"2008","unstructured":"Michur H, Maslanka K, Szczepinski A, Marianska B: Reticulated platelets as a marker of platelet recovery after allogeneic stem cell transplantation. Int J Lab Hematol. 2008, 30: 519-525.","journal-title":"Int J Lab Hematol"},{"key":"59_CR33","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s002770050513","volume":"78","author":"P Stohlawetz","year":"1999","unstructured":"Stohlawetz P, Stiegler G, Knobl P, Hocker P, Panzer S: The rise of reticulated platelets after intensive chemotherapy for AML reduces the need for platelet transfusions. Ann Hematol. 1999, 78: 271-273. 10.1007\/s002770050513.","journal-title":"Ann Hematol"},{"key":"59_CR34","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1002\/ajh.23116","volume":"87","author":"H Fredly","year":"2012","unstructured":"Fredly H, Reikvam H, Gjertsen BT, Bruserud O: Disease-stabilizing treatment with all-trans retinoic acid and valproic acid in acute myeloid leukemia: serum hsp70 and hsp90 levels and serum cytokine profiles are determined by the disease, patient age, and anti-leukemic treatment. Am J Hematol. 2012, 87: 368-376. 10.1002\/ajh.23116.","journal-title":"Am J Hematol"},{"key":"59_CR35","doi-asserted-by":"publisher","first-page":"3481","DOI":"10.1182\/blood-2005-09-3724","volume":"107","author":"FR Appelbaum","year":"2006","unstructured":"Appelbaum FR, Gundacker H, Head DR, Slovak ML, Willman CL, Godwin JE, Anderson JE, Petersdorf SH: Age and acute myeloid leukemia. Blood. 2006, 107: 3481-3485. 10.1182\/blood-2005-09-3724.","journal-title":"Blood"},{"key":"59_CR36","first-page":"1513","volume":"91","author":"B Deschler","year":"2006","unstructured":"Deschler B, de Witte T, Mertelsmann R, Lubbert M: Treatment decision-making for older patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: problems and approaches. Haematologica. 2006, 91: 1513-1522.","journal-title":"Haematologica"},{"key":"59_CR37","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1002\/cncr.22233","volume":"107","author":"B Deschler","year":"2006","unstructured":"Deschler B, Lubbert M: Acute myeloid leukemia: epidemiology and etiology. Cancer. 2006, 107: 2099-2107. 10.1002\/cncr.22233.","journal-title":"Cancer"},{"key":"59_CR38","doi-asserted-by":"publisher","first-page":"243","DOI":"10.2174\/157339409789712645","volume":"5","author":"H Fredly","year":"2009","unstructured":"Fredly H, Ersvaer E, Stapnes C, Gjertsen BT, Bruserud O: The combination of conventional chemotherapy with new targeted therapy in hematologic malignancies: the safety and efficiency of low-dose cytarabine supports its combination with new therapeutic agents in early clinical trials. Curr Cancer Ther Rev. 2009, 5: 243-255(213). 10.2174\/157339409789712645.","journal-title":"Curr Cancer Ther Rev"},{"key":"59_CR39","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1001\/archinte.162.14.1597","volume":"162","author":"J Menzin","year":"2002","unstructured":"Menzin J, Lang K, Earle CC, Kerney D, Mallick R: The outcomes and costs of acute myeloid leukemia among the elderly. Arch Intern Med. 2002, 162: 1597-1603. 10.1001\/archinte.162.14.1597.","journal-title":"Arch Intern Med"},{"key":"59_CR40","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1002\/cncr.22496","volume":"109","author":"AK Burnett","year":"2007","unstructured":"Burnett AK, Milligan D, Prentice AG, Goldstone AH, McMullin MF, Hills RK, Wheatley K: A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer. 2007, 109: 1114-1124. 10.1002\/cncr.22496.","journal-title":"Cancer"},{"key":"59_CR41","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1200\/JCO.2011.38.9429","volume":"30","author":"HM Kantarjian","year":"2012","unstructured":"Kantarjian HM, Thomas XG, Dmoszynska A, Wierzbowska A, Mazur G, Mayer J, Gau JP, Chou WC, Buckstein R, Cermak J: Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol. 2012, 30: 2670-2677. 10.1200\/JCO.2011.38.9429.","journal-title":"J Clin Oncol"},{"key":"59_CR42","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1182\/blood-2007-11-124602","volume":"112","author":"S Faderl","year":"2008","unstructured":"Faderl S, Ravandi F, Huang X, Garcia-Manero G, Ferrajoli A, Estrov Z, Borthakur G, Verstovsek S, Thomas DA, Kwari M, Kantarjian HM: A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood. 2008, 112: 1638-1645. 10.1182\/blood-2007-11-124602.","journal-title":"Blood"},{"key":"59_CR43","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1200\/JCO.2009.23.9178","volume":"28","author":"AF Cashen","year":"2010","unstructured":"Cashen AF, Schiller GJ, O'Donnell MR, DiPersio JF: Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. J Clin Oncol. 2010, 28: 556-561. 10.1200\/JCO.2009.23.9178.","journal-title":"J Clin Oncol"},{"key":"59_CR44","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1200\/JCO.2011.37.9743","volume":"30","author":"S Faderl","year":"2012","unstructured":"Faderl S, Wetzler M, Rizzieri D, Schiller G, Jagasia M, Stuart R, Ganguly S, Avigan D, Craig M, Collins R: Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I trial. J Clin Oncol. 2012, 30: 2492-2499. 10.1200\/JCO.2011.37.9743.","journal-title":"J Clin Oncol"},{"key":"59_CR45","doi-asserted-by":"publisher","first-page":"4471","DOI":"10.1002\/cncr.27429","volume":"118","author":"S Faderl","year":"2012","unstructured":"Faderl S, Ravandi F, Huang X, Wang X, Jabbour E, Garcia-Manero G, Kadia T, Ferrajoli A, Konopleva M, Borthakur G: Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients. Cancer. 2012, 118: 4471-4477. 10.1002\/cncr.27429.","journal-title":"Cancer"},{"key":"59_CR46","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1517\/13543784.17.11.1623","volume":"17","author":"A Ryningen","year":"2008","unstructured":"Ryningen A, Stapnes C, Paulsen K, Lassalle P, Gjertsen BT, Bruserud O: In vivo biological effects of ATRA in the treatment of AML. Expert Opin Investig Drugs. 2008, 17: 1623-1633. 10.1517\/13543784.17.11.1623.","journal-title":"Expert Opin Investig Drugs"},{"key":"59_CR47","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1182\/blood-2009-07-233387","volume":"115","author":"L Ades","year":"2010","unstructured":"Ades L, Guerci A, Raffoux E, Sanz M, Chevallier P, Lapusan S, Recher C, Thomas X, Rayon C, Castaigne S: Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience. Blood. 2010, 115: 1690-1696. 10.1182\/blood-2009-07-233387.","journal-title":"Blood"},{"key":"59_CR48","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1182\/blood.V94.4.1192","volume":"94","author":"P Fenaux","year":"1999","unstructured":"Fenaux P, Chastang C, Chevret S, Sanz M, Dombret H, Archimbaud E, Fey M, Rayon C, Huguet F, Sotto JJ: A randomized comparison of all-trans retinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood. 1999, 94: 1192-1200.","journal-title":"Blood"},{"key":"59_CR49","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/leu.2010.276","volume":"25","author":"A Quintas-Cardama","year":"2011","unstructured":"Quintas-Cardama A, Santos FP, Garcia-Manero G: Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemia. Leukemia. 2011, 25: 226-235. 10.1038\/leu.2010.276.","journal-title":"Leukemia"},{"key":"59_CR50","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1182\/blood-2007-06-098061","volume":"111","author":"G Garcia-Manero","year":"2008","unstructured":"Garcia-Manero G, Yang H, Bueso-Ramos C, Ferrajoli A, Cortes J, Wierda WG, Faderl S, Koller C, Morris G, Rosner G: Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid (SAHA) in patients with advanced leukemias and myelodysplastic syndromes. Blood. 2008, 111: 1060-1066.","journal-title":"Blood"},{"key":"59_CR51","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1365-2141.2010.08211.x","volume":"150","author":"TM Kadia","year":"2010","unstructured":"Kadia TM, Yang H, Ferrajoli A, Maddipotti S, Schroeder C, Madden TL, Holleran JL, Egorin MJ, Ravandi F, Thomas DA: A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukemia. Br J Haematol. 2010, 150: 72-82.","journal-title":"Br J Haematol"},{"key":"59_CR52","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1517\/13543784.2011.542750","volume":"20","author":"T Prebet","year":"2011","unstructured":"Prebet T, Vey N: Vorinostat in acute myeloid leukemia and myelodysplastic syndromes. Expert Opin Investig Drugs. 2011, 20: 287-295. 10.1517\/13543784.2011.542750.","journal-title":"Expert Opin Investig Drugs"},{"key":"59_CR53","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.3324\/haematol.2009.009217","volume":"94","author":"EW Schaefer","year":"2009","unstructured":"Schaefer EW, Loaiza-Bonilla A, Juckett M, DiPersio JF, Roy V, Slack J, Wu W, Laumann K, Espinoza-Delgado I, Gore SD: A phase 2 study of vorinostat in acute myeloid leukemia. Haematologica. 2009, 94: 1375-1382. 10.3324\/haematol.2009.009217.","journal-title":"Haematologica"},{"key":"59_CR54","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1182\/blood-2009-07-235358","volume":"115","author":"H Dohner","year":"2010","unstructured":"Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK, Dombret H, Fenaux P, Grimwade D, Larson RA: Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010, 115: 453-474. 10.1182\/blood-2009-07-235358.","journal-title":"Blood"},{"key":"59_CR55","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1111\/j.1600-0609.2005.00509.x","volume":"75","author":"F Wisloff","year":"2005","unstructured":"Wisloff F, Gulbrandsen N, Hjorth M, Lenhoff S, Fayers P: Quality of life may be affected more by disease parameters and response to therapy than by hemoglobin changes. Eur J Haematol. 2005, 75: 293-298. 10.1111\/j.1600-0609.2005.00509.x.","journal-title":"Eur J Haematol"},{"key":"59_CR56","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.3109\/10428194.2011.642302","volume":"53","author":"S Lane","year":"2012","unstructured":"Lane S, Gill D, McMillan NA, Saunders N, Murphy R, Spurr T, Keane C, Fan HM, Mollee P: Valproic acid combined with cytosine arabinoside in elderly patients with acute myeloid leukemia has in vitro but limited clinical activity. Leuk Lymphoma. 2012, 53: 1077-1083. 10.3109\/10428194.2011.642302.","journal-title":"Leuk Lymphoma"},{"key":"59_CR57","doi-asserted-by":"publisher","first-page":"34","DOI":"10.18632\/oncotarget.106","volume":"1","author":"E Raffoux","year":"2010","unstructured":"Raffoux E, Cras A, Recher C, Boelle PY, de Labarthe A, Turlure P, Marolleau JP, Reman O, Gardin C, Victor M: Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome. Oncotarget. 2010, 1: 34-42.","journal-title":"Oncotarget"},{"key":"59_CR58","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.1182\/blood-2007-03-078576","volume":"110","author":"AO Soriano","year":"2007","unstructured":"Soriano AO, Yang H, Faderl S, Estrov Z, Giles F, Ravandi F, Cortes J, Wierda WG, Ouzounian S, Quezada A: Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood. 2007, 110: 2302-2308. 10.1182\/blood-2007-03-078576.","journal-title":"Blood"},{"key":"59_CR59","doi-asserted-by":"crossref","unstructured":"Fredly H, Gjertsen BT, Bruserud O: Histone deacetylase inhibition in the treatment of acute myeloid leukemia - the effects of valproic acid on leukemic cells and the clinical and experimental evidence for combining valproic acid with other antileukemic agents. Clinical epigenetics. In Press","DOI":"10.1186\/1868-7083-5-12"},{"key":"59_CR60","first-page":"41","volume":"7","author":"S Amadori","year":"2013","unstructured":"Amadori S, Breccia M, Stasi R: Acute myeloid leukemia in older patients: conventional and new therapies. Haematologica. 2013, 7: 41-48.","journal-title":"Haematologica"},{"key":"59_CR61","volume-title":"The American Society of Hematology, Annual Meeting Abstracts, Volume 889","author":"A Burnett","year":"2012","unstructured":"Burnett A, Russell N, Kell J, Ali S, Moreton P, Kjeldsen L, Hills RK: A randomized comparison of clofarabine versus low dose Ara-C as first line treatment for older patients with AML. The American Society of Hematology, Annual Meeting Abstracts, Volume 889. 2012, Atlanta: the American Society for Hematology, 120","edition":"120"},{"key":"59_CR62","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1200\/JCO.2009.23.8329","volume":"28","author":"P Fenaux","year":"2010","unstructured":"Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Gattermann N, Germing U, Sanz G, List AF, Gore S, Seymour JF: Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol. 2010, 28: 562-569. 10.1200\/JCO.2009.23.8329.","journal-title":"J Clin Oncol"},{"key":"59_CR63","doi-asserted-by":"publisher","first-page":"7473","DOI":"10.1073\/pnas.1002650107","volume":"107","author":"W Blum","year":"2010","unstructured":"Blum W, Garzon R, Klisovic RB, Schwind S, Walker A, Geyer S, Liu S, Havelange V, Becker H, Schaaf L: Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci USA. 2010, 107: 7473-7478. 10.1073\/pnas.1002650107.","journal-title":"Proc Natl Acad Sci USA"},{"key":"59_CR64","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1200\/JCO.2012.48.1465","volume":"31","author":"H Kantarjian","year":"2013","unstructured":"Kantarjian H, Wilson W, Ravandi F, Estey E: Decitabine in older adults with acute myeloid leukemia: why was the dream broken?. J Clin Oncol. 2013, 31: 1795-1796. 10.1200\/JCO.2012.48.1465.","journal-title":"J Clin Oncol"}],"container-title":["Clinical Epigenetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1868-7083-5-13.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1868-7083-5-13\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1868-7083-5-13.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T21:31:42Z","timestamp":1715808702000},"score":1,"resource":{"primary":{"URL":"https:\/\/clinicalepigeneticsjournal.biomedcentral.com\/articles\/10.1186\/1868-7083-5-13"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,1]]},"references-count":64,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["59"],"URL":"https:\/\/doi.org\/10.1186\/1868-7083-5-13","relation":{},"ISSN":["1868-7075","1868-7083"],"issn-type":[{"value":"1868-7075","type":"print"},{"value":"1868-7083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,1]]},"article-number":"13"}}